Table 1. Characteristics of the 17 Included Trials.
| Trial | Recruitment period and location | Included histology | Treatment scheme per group (No. of patients with AEG per trial group included in meta-analysis) |
|---|---|---|---|
| IPD available | |||
| Ychou et al,12 2011 (ACCORD) | 1995-2003, France | Adenocarcinoma | Group A: cisplatin, 100 mg/m2, on day 1, fluorouracil, 800 mg/m2/d, on days 1-5, 2-3 preoperative and 3-4 postoperative cycles (n = 85); group B: surgery alone (n = 84) |
| Tepper et al,10 2008 (CALGB 9781) | 1997-2000, US | Adenocarcinoma and squamous cell carcinoma | Group A: preoperative simultaneous CRT, 50.4 Gy, cisplatin, 100 mg/m2, on days 1 and 29, fluorouracil, 1000 mg/m2, on days 1-4 and d 29-32 (n = 23); group B: surgery alone (n = 19) |
| Eyck et al,42021 (CROSS) | 2004-2008, the Netherlands | Adenocarcinoma and squamous cell carcinoma | Group A: preoperative simultaneous CRT, 41.4 Gy, and paclitaxel, 50 mg/m2, carboplatin (area under the curve, 2 mg/mL/min) (n = 134); group B: surgery alone (n = 141) |
| Schuhmacher et al,38 2010 (EORTC 40954) | 1999-2004, several European countries | Adenocarcinoma | Group A: cisplatin, 50 mg/m2, on days 1, 15, and 29, fluorouracil, 2000 mg/m2, on days 1, 8, 15, 22, and 36, 2 preoperative cycles (n = 37); group B: surgery alone (n = 39) |
| Mariette et al,37 2014 (FFCD 9901) | 2000-2009, France | Adenocarcinoma and squamous cell carcinoma | Group A: preoperative simultaneous CRT with 45 Gy, cisplatin, 75 mg/m2, on days 1 or 2 and 29 or 30, fluorouracil, 800 mg/m2, on days 1-4 and 29-32 (n = 30); group B: surgery alone (n = 27) |
| Cunningham et al,9 2006 (MAGIC) | 1994-2002, United Kingdom, the Netherlands, Germany, Singapore, New Zealand, and Brazil | Adenocarcinoma | Group A: epirubicin, 50 mg/m2, on day 1, cisplatin, 60 mg/m2, on day 1, fluorouracil, 200 mg/m2, on days 1 to 21, 3 preoperative and 3-4 postoperative cycles (n = 65); group B: surgery alone (n = 66) |
| von Döbeln et al,16 2019 (NeoRes) | 2006-2013, Sweden and Norway | Adenocarcinoma and squamous cell carcinoma | Group A: cisplatin, 100 mg/m2, day 1, fluorouracil, 750 mg/m2, days 1-5, 3 preoperative cycles (n = 66); group B: preoperative simultaneous CRT, 40 Gy, cisplatin, 100 mg/m2 on day 1, fluorouracil, 750 mg/m2, on days 1-5, 3 preoperative cycles (n = 65) |
| Allum et al,8 2009 (OE02) | 1992-1998, European countries | Adenocarcinoma and squamous cell carcinoma | Group A: cisplatin, 80 mg/m2, on day 1, fluorouracil, 1000 mg/m2, on days 1-4, 2 preoperative cycles (n = 265); group B: surgery alone (n = 268) |
| Stahl et al,15 2017 (POET) | 2000-2005, Germany | Adenocarcinoma | Group A: cisplatin, 50 mg/m2, biweekly, fluorouracil, 2000 mg/m2, weekly, 2.5 preoperative cycles (n = 59); group B: cisplatin, 50 mg/m2, biweekly, fluorouracil, 2000 mg/m2, weekly, 2 preoperative cycles followed by preoperative simultaneous CRT, 30 Gy, cisplatin, 50 mg/m2, on days 1-8, etoposide, 80 mg/m2, on days 3-5 (n = 60) |
| Kelsen et al,36 2007 (RTOG 8911) | 1990-1995, US and Canada | Adenocarcinoma and squamous cell carcinoma | Group A: cisplatin,100 mg/m2, on day 1, fluorouracil, 1000 mg/m2, on days 1-5, 2 preoperative cycles (n = 121); group B: surgery alone (n = 126) |
| Burmeister et al,14 2011 (TROG) | 2000-2006, Australia and New Zealand | Adenocarcinoma | Group A: cisplatin, 80 mg/m2, on day 1, fluorouracil, 1000 mg/m2, on days 1-4, 2 preoperative cycles (n = 38); group B: cisplatin, 80 mg/m2, on day 1, fluorouracil, 1000 mg/m2, on days 1-4, 2 preoperative cycles, simultaneous radiotherapy, 35 Gy, 15 fractions, with second cycle with fluorouracil reduced to 800 mg/m2 (n = 39) |
| Burmeister et al,35 2005 (TROG AGITG) | 2000-2006, Australia and New Zealand | Adenocarcinoma and squamous cell carcinoma | Group A: preoperative simultaneous CRT, 35 Gy, cisplatin, 80 mg/m2, on day 1, fluorouracil, 800 mg/m2, on days 1-4, 2 preoperative cycles (n = 80); group B: surgery alone (n = 78) |
| Urba et al,40 2001 | 1989-1994, US | Adenocarcinoma and squamous cell carcinoma | Group A: preoperative simultaneous CRT, 45 Gy, cisplatin, 20 mg/m2, on days 1-5 and 17-21, fluorouracil, 300 mg/m2, on days 1-21, vinblastine, 1 mg/m2, on days 1-4 and 17-21 (n = 37); group B: surgery alone (n = 39) |
| Walsh et al,11 1996 | 1990-1995, Ireland | Adenocarcinoma | Group A: preoperative simultaneous CRT, 40 Gy, cisplatin, 75 mg/m2, on days 7 and 49, fluorouracil, 15 mg/kg on days 1-5 and 42-47 (n = 58); group B: surgery alone (n = 55) |
| IPD unavailable | |||
| Tian et al,39 2021 | 2012-2016, China | Adenocarcinoma | Group A: preoperative simultaneous CRT, 45 Gy, capecitabine, 1000 mg/m2, twice daily on days 1-14, oxaliplatin, 130 mg/m2, on day 1, 2 preoperative cycles, 6 postoperative cycles (n = 76); group B: surgery alone (n = 73) |
| Leong et al,19 2017 | 2009-2014, Australia, New Zealand, and Belgium, Germany, Canada | Adenocarcinoma | Group A: epirubicin, 50 mg/m2, on day 1, cisplatin, 60 mg/m2, on day 1, fluorouracil, 200 mg/m2 for 21-d continuous infusion, 3 preoperative cycles, 3 postoperative cycles (n = 60); group B: epirubicin, 50 mg/m2, on day 1, cisplatin, 60 mg/m2, on day 1, fluorouracil, 200 mg/m2, for 21-d continuous infusion, 2 preoperative cycles, simultaneous CRT, 45 Gy, continuous fluorouracil, 200 mg/m2, on days 1-25, epirubicin, 50 mg/m2, on day 1, cisplatin, 60 mg/m2, on day 1, fluorouracil, 200 mg/m2, 21-d continuous infusion, 3 postoperative cycles (n = 60) |
| Zhao et al,41 2015 | 2012-2013, China | Adenocarcinoma | Group A: preoperative simultaneous CRT, 45 Gy, oxaliplatin, 130 mg/m2, on day 1, capecitabine, 2000 mg/m2, on days 1-14 (n = 36); group B: surgery alone (n = 40) |
Abbreviations: ACCORD, Actions Concertées dans les Cancers Colo-Rectaux et Digestifs; AEG, adenocarcinoma of the esophagus or esophageal junction; AGITG, Australasian Gastro-Intestinal Trials Group; CALGB, Cancer and Leukemia Group B; CROSS, Chemoradiotherapy for Oesophageal Cancer Followed by Surgery Study; CRT, chemoradiotherapy; EORTC, European Organisation for Research and Treatment of Cancer; FFCD, Federation Francophone de Cancerologie Digestive; IPD, individual patient data; MAGIC, Medical Research Council Adjuvant Gastric Infusional Chemotherapy; NeoRes, Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia; POET, Preoperative Therapy in Esophagogastric Adenocarcinoma Trial; RTOG, Radiation Therapy Oncology Group; TROG, Trans Tasman Radiation Oncology Group.